Parthenon Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment, today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published results from an international panel of cancer experts convened to provide an initial consensus on the role of immune exclusion in cancer.

The article “Developing a Definition of Immune Exclusion in Cancer: Results of a Modified Delphi Workshop,” identifies key characteristics of and issues relevant to the role immune exclusion plays in resistance to checkpoint therapy and is now available online. The work described in the paper was performed in collaboration with multiple US and international academic institutions.

“Immune exclusion until now has not had a well-defined profile, but we know it exists across multiple tumor types,” said J. Paul Eder, MD, Chief Medical Officer of Parthenon Therapeutics. “In collaboration with academic leaders, Parthenon is pioneering how to recognize and define immune exclusion in cancer and understand the mechanisms underlying it. By modulating the tumor microenvironment and breaking down the barrier that tumors construct to protect them from an immune attack, we think we can overcome immune exclusion and thus, improve patient outcomes.”

Parthenon recently initiated a Phase 1 trial for its lead candidate PRTH-101 first-in-human clinical trial in patients with immune-excluded solid tumors (NCT05753722).
 

Source:businesswire.com